Three-dimensional cell-culturing technology developed and marketed by Nano3D Biosciences (n3D) and Rainbow Biosciences, a biotech subsidiary of Rainbow Coral Corp. (OTCBB: RBCC), could hold the key to gaining new insights into the growth and spread of cancer cells.
The preeminent review journal
Nature Reviews Cancer
recently published a review written by n3D co-founder Dr. Glauco Souza and science advisor Dr. Jeanne L. Becker on the influence of microgravity on cell biology. In the microgravity environment of outer space, cells assemble into multicellular, 3D constructs. By simulating microgravity growth environments, scientists can study cell-to-cell interaction unrestricted by gravity—crucial to defining the biology of cancer cells and tissue, including tumor formation and progression.
The review includes detailed descriptions of n3D’s groundbreaking cell culture levitation system, known as the Bio-Assembler, as an analog method for culturing cells in space. It’s a high-profile piece that RBCC CEO Patrick Brown expects to be a major asset in the company’s mission to spread the word about the Bio-Assembler. RBCC formed a joint venture with n3D to market and develop the Bio-Assembler last year.
“Cancer research using the Bio-Assembler may soon prove key to the development of new anti-cancer technologies and therapies,” Brown said. “It’s the next best thing to conducting these experiments in outer space.”
Rainbow Biosciences is dedicated to the marketing and development of new medical and research technology innovations designed to help capture a growing share of a booming biotech industry alongside Bristol Myers Squibb Co. (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN).
For more information on RBCC’s partnership with n3D and other biotech initiatives, please visit
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit
. For investment information and performance data on the Company, please visit
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.